Skip to main content

Table 3 Analysis of CD39 immunostaining intensity by study group

From: Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD

CD39 Stain Score for lung parenchyma

COPD

NOS

NS

+++

1 (6,66)

0 (0)

1 (8,33)

++

3 (20)

8 (61,53)

6 (50)

+

10 (66,66)

4 (30,78)

4 (33,33)

0

1 (6,66)

1 (7,69)

1 (8,33)

Total of Samples

15

13

12

CD39 Stain Score for the Bronchi

COPD

NOS

NS

+++

5 (12,82)

16 (25,4)

25 (40,32)

++

9 (23,08)

30 (47,62)

29 (46,77)

+

21 (53,84)

17 (26,98)

8 (12,9)

0

4 (10,25)

0 (0)

0 (0)

Total of Bronchus

39

63

62

Total of Samples

12

12

12

CD39 Stain Score for the Muscular Pulmonary Artery

COPD

NOS

NS

+++

20 (9,13)

7 (4,46)

19 (17,59)

++

38 (17,35)

52 (33,12)

39 (36,11)

+

80 (36,53)

58 (36,94)

43 (39,81)

0

81 (36,98)

40 (25,48)

7 (6,48)

Total of Pulmonary Artery

219

157

108

Total of Samples

15

13

12

  1. COPD Chronic Obstructive Pulmonary Disease, NOS Non-obstructed smokers, NS Never smokers. Number of samples, Stain Intensity and Percentage are shown for each result